Data mining of severe cutaneous adverse reactions related to immune checkpoint inhibitors in the FAERS

LONG Xia; HUANG Mengwen; PU Shiyun; WANG Lichen; TANG Mengjiao; ZHOU Houfeng

doi:10.6039/j.issn.1001-0408.2023.22.13

您当前的位置：

首页 >

文章列表页 >

Data mining of severe cutaneous adverse reactions related to immune checkpoint inhibitors in the FAERS

更新时间：2023-11-25

- Data mining of severe cutaneous adverse reactions related to immune checkpoint inhibitors in the FAERS
- ZHONGGUO YAOFANG Vol. 34, Issue 22, Pages: 2760-2765(2023)
- 作者机构：
  
  1.成都市第五人民医院药剂科，成都　611130
  2.成都中医药大学药学院，成都　611137
  3.川北医学院药学院，四川南充　637100
  4.西南医科大学药学院，四川泸州　646099
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.22.13
  CLC： R969.3
- Published：30 November 2023，
  
  Received：27 April 2023，
  
  Revised：08 September 2023，
扫描看全文
龙霞,黄孟文,蒲诗云等.FAERS中免疫检查点抑制剂相关严重皮肤不良反应数据挖掘 ^Δ[J].中国药房,2023,34(22):2760-2765.

LONG Xia,HUANG Mengwen,PU Shiyun,et al.Data mining of severe cutaneous adverse reactions related to immune checkpoint inhibitors in the FAERS[J].ZHONGGUO YAOFANG,2023,34(22):2760-2765.
龙霞,黄孟文,蒲诗云等.FAERS中免疫检查点抑制剂相关严重皮肤不良反应数据挖掘 ^Δ[J].中国药房,2023,34(22):2760-2765. DOI： 10.6039/j.issn.1001-0408.2023.22.13.

LONG Xia,HUANG Mengwen,PU Shiyun,et al.Data mining of severe cutaneous adverse reactions related to immune checkpoint inhibitors in the FAERS[J].ZHONGGUO YAOFANG,2023,34(22):2760-2765. DOI： 10.6039/j.issn.1001-0408.2023.22.13.

摘要

目的

挖掘并分析5种常用免疫检查点抑制剂（ICIs）相关严重皮肤不良反应信号，为临床安全用药提供参考。

方法

从美国FDA不良事件报告系统（FAERS）数据库中收集伊匹木单抗、纳武利尤单抗、帕博利珠单抗、阿替利珠单抗和度伐利尤单抗自美国上市至2022年第4季度相关严重皮肤不良反应的药物不良事件（ADEs）报告，采用报告比值比（ROR）法和贝叶斯置信区间递进神经网络（BCPNN）法对信号进行挖掘与分析。

结果

共收集到严重皮肤不良反应报告5 726份，其中纳武利尤单抗3 037份、帕博利珠单抗1 465份、度伐利尤单抗130份、阿替利珠单抗429份、伊匹木单抗665份。5种ICIs均生成了阳性信号，其关联度由强到弱依次是帕博利珠单抗＞阿替利珠单抗＞纳武利尤单抗＞伊匹木单抗＞度伐利尤单抗。5种ICIs均有报告史-约综合征和中毒性表皮坏死松解症发生，关联度均以帕博利珠单抗最强。

结论

5种ICIs均有导致严重皮肤不良反应发生的风险，临床在使用时应密切关注，尤其在使用帕博利珠单抗时应特别谨慎；同时，应尽量避免ICIs之间的联用。

Abstract

OBJECTIVE

To mine and analyze severe cutaneous adverse reaction signals of 5 commonly used immune checkpoint inhibitors （ICIs）， and to provide reference for clinically safe use of drugs.

METHODS

Based on the FDA adverse events reporting system （FAERS） database，adverse drug events （ADEs） reports about severe cutaneous adverse reactions related to ipilimumab， nivolumab， pembrolizumab， atezolizumab and durvalumab were collected from listing in the United States to the fourth quarter of 2022. The ADE signals were mined and analyzed with reporting odds ratio （ROR） and Bayesian confidence propagation neural network （BCPNN）.

RESULTS

A total of 5 726 reports of severe cutaneous adverse reactions were collected， including 3 037 reports for nivolumab，1 465 reports for pembrolizumab， 130 reports for durvalumab， 429 reports for atezolizumab and 665 reports for ipilimumab. All 5 kinds of ICIs caused positive signals， the correlation degree of which was as follows： pembrolizumab＞atezolizumab＞nivolumab＞ipilimumab＞durvalumab. Stevens-Johnson syndrome（SJS）and toxic epidermal necrolysis （TEN） have been reported for all 5 ICIs， and the association was the strongest with pembrolizumab.

CONCLUSIONS

All 5 kinds of ICIs are associated with the risk of severe skin adverse reactions， and close attention should be paid to their clinical use， especially being cautious when using pembrolizumab. The combination of ICIs should be avoided as much as possible.

关键词

免疫检查点抑制剂严重皮肤不良反应药物不良事件信号检测

Keywords

severe cutaneous adverse reactionsadverse drug reactionssignal detection

references

郭雪美，周佳鑫，张文. 免疫检查点抑制剂相关风湿性不良反应的诊疗进展[J]. 临床内科杂志，2023，40（2）：82-85.

GUO X M，ZHOU J X，ZHANG W. Progress in diagnosis and treatment of rheumatic adverse events associated with immune checkpoint inhibitors[J]. J Clin Intern Med，2023，40（2）：82-85.

金相红，张炎，庄俊玲. 免疫检查点抑制剂相关血液学毒性的诊治进展[J]. 临床内科杂志，2023，40（2）：73-78.

JIN X H，ZHANG Y，ZHUANG J L. Progress in diagnosis and treatment of hematologic toxicity associated with immune checkpoint inhibitors[J]. J Clin Intern Med，2023，40（2）：73-78.

吴汀溪，张杨，石延枫，等. 基于美国FAERS数据库对免疫检查点抑制剂相关神经毒性的分析研究[J]. 中国药物应用与监测，2023，20（1）：50-54.

WU T X，ZHANG Y，SHI Y F，et al. Analysis of neurological toxicities associated with immune checkpoint inhibitor based on the FDA adverse event reporting system[J]. Chin J Drug Appl Monit，2023，20（1）：50-54.

TANG S Q，TANG L L，MAO Y P，et al. The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer：a pooled analysis of 23 clinical trials and 8 436 patients[J]. Cancer Res Treat，2021，53（2）：339-354.

THOMPSON J A，SCHNEIDER B J，BRAHMER J，et al. Management of immunotherapy-related toxicities，version 1.2019[J]. J Natl Compr Canc Netw，2019，17（3）：255-289.

李厚荣，邹振亚. 免疫检查点抑制剂致皮肤不良反应及其管理的研究进展[J]. 临床皮肤科杂志，2023，52（3）：187-189.

LI H R，ZOU Z Y. Research progress and management strategies about skin adverse reactions of immune checkpoint inhibitors[J]. J Clin Dermatol，2023，52（3）：187-189.

邹美熔，汪盛. 免疫检查点抑制剂所致皮肤免疫相关不良反应的研究进展[J]. 中华皮肤科杂志，2022，55（11）：1026-1030.

ZOU M R，WANG S. Cutaneous immune-related adverse reactions induced by immune checkpoint inhibitors[J]. Chin J Dermatol，2022，55（11）：1026-1030.

范秀丛，白荣，李语玲，等. 帕博利珠单抗致致死性Stevens-Johnson综合征/中毒性表皮坏死松解症1例[J]. 中国医院药学杂志，2021，41（12）：1281-1282.

FAN X C，BAI R，LI Y L，et al. Fatal Stevens-Johnson syndrome/toxic epidermal necrolysis caused by pembrolizumab：one case report[J]. Chin J Hosp Pharm，2021，41（12）：1281-1282.

苏逸，王青青，王萌冉，等. 免疫检查点抑制剂相关中毒性表皮坏死松解症1例[J]. 中国临床实用医学，2022，13（2）：77-78.

SU Y，WANG Q Q，WANG M R，et al. A case of toxic epidermal necrolysis associated with immune checkpoint inhibitor[J]. China Clin Pract Med，2022，13（2）：77-78.

谢一航，沈云，施辛，等. 纳武利尤单抗诱导的中毒性表皮坏死松解症1例[J]. 中华皮肤科杂志，2022，55（12）：1103-1105.

XIE Y H，SHEN Y，SHI X，et al. A case of toxic epidermal necrolysis induced by nivolumab[J]. Chin J Dermatol，2022，55（12）：1103-1105.

中华医学会皮肤性病学分会药物不良反应研究中心. Stevens-Johnson综合征/中毒性表皮坏死松解症诊疗专家共识[J]. 中华皮肤科杂志，2021，54（5）：376-381.

Adverse Drug Reaction Research Center of Chinese So-ciety of Dermatology. Expert consensus on the diagnosis and treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis[J]. Chin J Dermatol，2021，54（5）：376-381.

赛尔比亚·玉努斯阿吉，熊代琴，吴斌，等. 基于FAERS的糖皮质激素类药物相关骨质疏松及骨坏死类事件数据挖掘研究[J]. 医药导报，2023，42（4）：591-596.

SARBIYA·YUNUSAJI，XIONG D Q，WU B，et al. FAERS-based data mining study of glucocorticoid-drug related osteoporosis and osteonecrosis[J]. Her Med，2023，42（4）：591-596.

HUANG J，ZHAO Y B，CAO Y N，et al. Anaplastic lymphoma kinase tyrosine kinase inhibitors associated gastrointestinal obstruction，perforation，and ulceration：an analysis of the FDA adverse event reporting system database（FAERS）[J]. Int J Clin Pharm，2022，44（4）：993-1003.

龙霞，干小红，曾晓欢. 瑞戈非尼的安全警戒信号检测与评价[J]. 中国医院药学杂志，2019，39（15）：1573-1577.

LONG X，GAN X H，ZENG X H. Signals detection and evaluation of adverse reaction induced by regorafenib[J]. Chin J Hosp Pharm，2019，39（15）：1573-1577.

PULEO J，POLYAK K. A Darwinian perspective on tumor immune evasion[J]. Biochim Biophys Acta Rev Cancer，2022，1877（1）：188671.

张文欣，郭弘洁，潘孝汇，等. 免疫检查点抑制剂的研究进展[J]. 药学进展，2022，46（12）：910-921.

ZHANG W X，GUO H J，PAN X H，et al. Research pro-gress of immune checkpoint inhibitors[J]. Prog Pharm Sci，2022，46（12）：910-921.

MELLMAN I，COUKOS G，DRANOFF G. Cancer immunotherapy comes of age[J]. Nature，2011，480（7378）：480-489.

INTHAGARD J，EDWARDS J，ROSEWEIR A K. Immunotherapy：enhancing the efficacy of this promising therapeutic in multiple cancers[J]. Clin Sci，2019，133（2）：181-193.

白黎，王珂. 免疫检查点抑制剂导致免疫相关不良反应的研究进展[J]. 长春中医药大学学报，2023，39（2）：229-236.

BAI L，WANG K. Research progress of immune-related adverse reactions caused by immune checkpoint inhibitors[J]. J Chang Univ Chin Med，2023，39（2）：229-236.

张晶，秦晓涵，都乐，等. 免疫检查点抑制剂相关非心肌炎心脏毒性的诊疗进展[J]. 临床内科杂志，2023，40（2）：79-82.

ZHANG J，QIN X H，DU L，et al. Progress in diagnosis and treatment of non-myocarditis cardiotoxicity asso-ciated with immune checkpoint inhibitors[J]. J Clin Intern Med，2023，40（2）：79-82.

ZHANG L L，REYNOLDS K L，LYON A R，et al. The evolving immunotherapy landscape and the epidemiology，diagnosis，and management of cardiotoxicity：JACC： CardioOncology primer[J]. JACC CardioOncol，2021，3（1）：35-47.

WALIANY S，LEE D，WITTELES R M，et al. Immune checkpoint inhibitor cardiotoxicity：understanding basic mechanisms and clinical characteristics and finding a cure[J]. Annu Rev Pharmacol Toxicol，2021，61：113-134.

李子航，王睿，马亮，等. 免疫检查点抑制剂致严重皮肤不良事件文献分析[J]. 中国药物应用与监测，2022，19（5）：326-330，349.

LI Z H，WANG R，MA L，et al. Literature analysis of severe skin adverse event induced by immune checkpoint inhibitors[J]. Chin J Drug Appl Monit，2022，19（5）：326-330，349.

程海星，张道军，郝飞. 免疫检查点抑制剂相关的皮肤不良反应[J]. 中国皮肤性病学杂志，2023，37（6）：727-731.

CHENG H X，ZHANG D J，HAO F. Skin adverse reactions associated with immune checkpoint inhibitors[J]. Chin J Dermatovenereol，2023，37（6）：727-731.

PANPRUK R，PUANGSRICHARERN V，KLAEWSONGKRAM J，et al. Clinical parameters and biological markers associated with acute severe ocular complications in Stevens-Johnson syndrome and toxic epidermal necrolysis[J]. Sci Rep，2021，11（1）：20275.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Detection and evaluation of the signals of amlodipine and lercanidipine based on FAERS database

Data Analysis of the Risks of Abnormal Female Reproductive System Haemorrhages Induced by Novel Oral An- ticoagulants Based on FAERS

Related Author

ZHONG Guizun

ZHANG Ni

WANG Hongli

CHEN Siqi

GONG Li

PAN Lingyun

JIA Yuntao

TIAN Xiaojiang

Related Institution

School of Pharmacy，Chongqing Medical University

Dept. of Pharmacy， Army Medical Characteristic Center of PLA

Key Lab of Researches on Transformation of Tumor Metastasis and Individualized Diagnosis and Treatment， Chongqing University Cancer Hospital

Dept. of Pharmacy， Chongqing University Cancer Hospital

Dept. of Pharmacy， Children’s Hospital Affiliated to Chongqing Medical University/Key Laboratory of Child Development Disease Research， Ministry of Education/National Science and Technology Cooperation Base of Major Child Development Diseases/Chongqing Key Laboratory of Pediatrics/National Clinical Medicine Research Center of Child Health and Diseases

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰